Sennosides

Summary

Sennosides (CHEMBL2108559) is a phase-3 clinical-stage unknown; indicated across 2 conditions including rectal cancer and colonic neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108559
Name	Sennosides
Type	Unknown
Max phase	3

Also known as: Calcium sennoside, Calcium sennosides, Colonorm, Glysennid, Nytilax, Pursennid, Pursennide, Sennoside, Sennoside ca, Sennosides, Sennosides (as calcium), SID555084

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rectal cancer	3	MONDO:0006519	EFO:1000657
colonic neoplasm	3	MONDO:0005401	MONDO:0021063

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
Not specified	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01531140	PHASE4	COMPLETED	PEG Versus PEG+Bisacodyl Versus Sennosides for Colon Cleansing Before Colonoscopy
NCT00902031	Not specified	COMPLETED	Effectiveness of Docusate in Preventing/Treating Constipation in Palliative Care Patients
NCT02618564	Not specified	COMPLETED	The Use of Sennosides With Pico Salax in Bowel Preparation for Colonoscopy: a Study of Optimal Dose and Timing

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).